½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1304299

¾Ï Ä¡·áÁ¦ ½ÃÀå : ¾à¹° À¯Çüº°, ÀûÀÀÁõº°, Áö¿ªº° ½ÃÀå ±Ô¸ð, Á¡À¯À², Àü¸Á ¹× ±âȸ ºÐ¼®(2023-2030³â)

Cancer Drugs Market, By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and By Indication By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾ÏÀº ½ÅüÀÇ ÀϺΠ¼¼Æ÷°¡ ÅëÁ¦ÇÒ ¼ö ¾øÀ» Á¤µµ·Î Áõ½ÄÇÏ¿© ½ÅüÀÇ ´Ù¸¥ ºÎÀ§·Î ÀüÀ̵Ǵ °¡Àå Ä¡¸íÀûÀÎ Áúº´ÀÔ´Ï´Ù. È­Çпä¹ý, È£¸£¸ó ¿ä¹ý, Ç¥ÀûÇ×¾ÏÁ¦, ¸é¿ªÄ¡·áÁ¦, ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ® Á¦Á¦¿Í °°Àº ¾Ï Ä¡·áÁ¦´Â ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌó·³ ¾ÏÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾ÈÀüÇÏ°í È¿°úÀûÀÎ ¾Ï Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿äµµ ¼¼°èÀûÀ¸·Î ºü¸£°Ô Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

¾Ï À¯º´·ü Áõ°¡, ³ë·É Àα¸ Áõ°¡, ¾ÈÀüÇÏ°í È¿°úÀûÀÎ ¾Ï Ä¡·áÁ¦¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä, ¾Ï°ú ¾Ï Ä¡·áÁ¦¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀÎ½Ä Áõ°¡, ¾Ï Ä¡·á ¼¾ÅÍ Áõ°¡ µîÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµÇ´Â ¿äÀÎÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Ư¡

  • ÀÌ º¸°í¼­´Â ¼¼°è ¾Ï Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2022³âÀ» ±âÁØ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2023-2030³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR) Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ÆľÇÇÏ°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÑ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °í·Á »çÇ×µµ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µî ´ÙÀ½°ú °°Àº ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • º» Á¶»ç ´ë»óÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Pfizer Inc., Novartis AG, Merck & Co., Inc., Celgene Corporation, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson£¨Janssen Global Services, LLC) µîÀÌ ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆà ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆà Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è ¾Ï Ä¡·áÁ¦ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¾Ï Ä¡·áÁ¦ ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå »óȲ °³¿ä

  • º¸°í¼­ °³¿ä
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â ¾Ï ºÎ´ã
    • ¾Ï Ä¡·áÁ¦ÀÇ ºÎÀÛ¿ë
    • ¾ÈÀüÇÏ°í È¿°úÀûÀÎ ÀǾàÇ° ¼ö¿ä Áõ°¡
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À

Á¦4Àå ¼¼°èÀÇ ¾Ï Ä¡·áÁ¦ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
  • °æÁ¦Àû ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¾Ï Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½º ŸÀÔº°, 2023-2030³â

  • È­Çпä¹ý
  • Ç¥ÀûÄ¡·á
  • È£¸£¸ó ¿ä¹ý

Á¦6Àå ¼¼°èÀÇ ¾Ï Ä¡·áÁ¦ ½ÃÀå, ÀûÀÀÁõº°, 2023-2030³â

  • ¼­·Ð
  • Æó¾Ï
  • À§¾Ï
  • ´ëÀå¾Ï
  • À¯¹æ¾Ï
  • Àü¸³¼±¾Ï
  • °£¾Ï
  • ½Äµµ¾Ï
  • ÀڱðæºÎ¾Ï
  • ½ÅÀå¾Ï
  • ¹æ±¤¾Ï
  • ±âŸ ¾Ï

Á¦7Àå ¼¼°èÀÇ ¾Ï Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°, 2023³â-2030³â

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï ±¸µµ

  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Celgene Corporation
  • AstraZeneca PLC
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson(Janssen Global Services, LLC)

Á¦9Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆǻ翡 ´ëÇØ
LSH 23.08.09

Cancer is a most lethal disease in which some of the body's cells grow uncontrollably and spread to other parts of the body. Cancer drugs, such as chemotherapy, hormone therapies, targeted cancer drugs, immunotherapy drugs, and bisphosphonates, among others, are used to treat different types of cancer. Thus, with the rise in burden of cancer, the demand for safe and effective cancer drugs is also increasing with a rapid pace, worldwide.

Market Dynamics:

Increasing prevalence of cancer, growing geriatric population, high demand for safe and effective cancer drugs, increasing awareness among people about a cancer and cancer drugs, and increasing number of cancer treatment centres are factors expected to augment the growth of the global cancer drugs market during the forecast period.

For instance, according to the American Cancer Society (ACS), in 2023, more than 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. While, in 2022, around 1.9 Billion new cancer cases and 609,360 cancer deaths were projected to occur in the U.S. Moreover, according to the cancer report by Indian Council of Medical Research (ICMR), India's cancer cases could increase by 12% in the next five years, with around 1.5 Billion people projected to suffer from the non-communicable disease by 2025, up from 1.39 Billion in 2020.

Key features of the study:

  • This report provides in-depth analysis of the global cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., Celgene Corporation, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, and Johnson & Johnson (Janssen Global Services, LLC), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer drugs market.

Detailed Segmentation:

  • Global Cancer Drugs Market, By Drug Class Type:
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy (Biologic Therapy)
    • Hormonal Therapy)
  • Global Cancer Drugs Market, By Indication:
    • Lung Cancer
    • Stomach Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Prostate Cancer
    • Liver Cancer
    • Esophagus Cancer
    • Cervical Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Other Cancer
  • Global Cancer Drugs Market, By Geography:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Celgene Corporation
    • AstraZeneca PLC
    • Astellas Pharma Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson (Janssen Global Services, LLC)

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class Type
    • Market Snapshot, By Indication
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing burden of cancer across the globe
    • Adverse effects of cancer drugs
    • Growing demand for safe and effective drugs
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Cancer Drugs Market, By Drug Class Type, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Targeted Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
    • Immunotherapy (Biologic Therapy)
  • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Hormonal Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

6. Global Cancer Drugs Market, By Indication, 2023-2030, (US$ Bn)

  • Intzroduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Stomach Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Liver Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Esophagus Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Cervical Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Kidney Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Bladder Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Other Cancers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

7. Global Cancer Drugs Market, By Region, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2023-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)

8. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Celgene Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • F. Hoffmann-La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson (Janssen Global Services, LLC)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦